Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + bevacizumab showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + bevacizumab showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (moderate certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
1 finding from 1 review
Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether everolimus + bevacizumab changes progression‐free survival (absolute effect size estimates based on… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether everolimus + bevacizumab changes overall survival (absolute effect size estimates based on survival… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Everolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (low certainty).
1 finding from 1 review
Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib may leads to higher progression‐free survival (absolute effect size estimates based on… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
1 finding from 1 review
treatment efficacyup to 6 months (8‐10 weeks) · depression in adults
Behavioural activation may leads to higher treatment efficacyup to 6 months (8‐10 weeks) compared with humanistic therapy (low certainty).
1 finding from 1 review
treatment acceptabilityup to 6 months (1 to 10 weeks) · depression in adults
It is very uncertain whether behavioural activation changes treatment acceptabilityup to 6 months (2‐10 weeks) compared with humanistic therapy (very low certainty).
1 finding from 1 review
depression symptoms(continuous) up to 6 months (1 to 10 weeks) · depression in adults
1 finding from 1 review
quality of life (continuous)up to 6 months (2 weeks) · depression in adults
1 finding from 1 review
Anxiety · depression in adults
1 finding from 1 review
Death Analysis 1.1 · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).
1 finding from 1 review
Major bleeding · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
1 finding from 1 review
Thrombosis‐related mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found